Document is current
Any future updates will be listed below
-
Authors
Gregory, Justin M.
Smith, T. Jordan
Duffus, Sara H.
Brooks, David
Akbar, M. Naweed
Huntley, Margaret-Anne
Gottlieb, JoAnn A.
LeStourgeon, Lauren M.
Wilson, Christopher S.
Beckman, Joshua A.
Cherrington, Alan D.
-
Funding
Funding for this research was provided by:
Juvenile Diabetes Research Foundation United States of America (5-ECR-2020-950-A-N)
National Institute of Diabetes and Digestive and Kidney Diseases (DK123392)
National Institute of Diabetes and Digestive and Kidney Diseases (DK00706)
National Center for Advancing Translational Sciences (TR002243)
- License Information
-
More Information
Article History
Received: 18 December 2024
Accepted: 19 February 2025
First Online: 5 March 2025
Declarations
:
: All participants provided written informed consent. The study was approved by the Vanderbilt University Institutional Review Board and registered at ClinicalTrials.gov (NCT04118374).
: Not applicable.
: J.M.G. has received consulting fees from vTV therapeutics, DRI Capital Inc., Beckman Coulter Inc., and Sanofi; reimbursement for serving on scientific advisory committees for vTV therapeutics and Sanofi; honoraria for educational events with MJH Life Sciences; and payments for participation on a clinical events committee for Medtronic. J.A.B. has received consulting fees from Cook, JanOne, Merck, Medtronic, Novartis, and Tourmaline. A.D.C. serves on scientific advisory boards or as a consultant for AdipoPharma, Fractyl Health, Inc., Pioneering Medicine, Portal Insulin, Sekkei Bio, and Sensulin Labs, LLC. Abvance, Novo Nordisk, Paratus, and Thetis Pharmaceuticals, LLC; and is receiving research grant support from Abvance, Alnylam, and Novo Nordisk.
